IN-VITRO ACTIVITY OF QUINOLONES AND MACROLIDES AGAINST MYCOBACTERIA

被引:72
作者
YEW, WW
PIDDOCK, LJV
LI, MSK
LYON, D
CHAN, CY
CHENG, AFB
机构
[1] CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG
[2] GRANTHAM HOSP,TB & CHEST UNIT,ABERDEEN,HONG KONG
[3] UNIV BIRMINGHAM,DEPT INFECT,BIRMINGHAM,W MIDLANDS,ENGLAND
关键词
D O I
10.1093/jac/34.3.343
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activities of eight quinolones (ciprofloxacin, clinafloxacin, levofloxacin, oflox-acin, A-80556, sparfloxacin, temafloxacin and tosufloxacin) and three macrolides (azithromycin, clarithromycin and erythromycin) against 98 clinical isolates of Mycobacterium tuberculosis and 120 isolates of five different atypical mycobacterial species including 20 Mycobacterium kansasii, 25 Mycobacterium scrofulaceum, 25 Mycobacterium avium/intracellulare, 25 Mycobacterium chelonae and 25 Mycobacterium fortuitum were determined with the Middlebrook 7H9 broth macro-dilution method. Sparfloxacin, clinafloxacin, levofloxacin, ciprofloxacin and oflox-acin were active against M. tuberculosis (MIC90 0.06-0.5 mg/L; MBC90 0.125-2.0 mg/L). However, higher MIC90S and MBC90s of these quinolones were obtained for strains of multi-drug resistant M. tuberculosis. The macrolides tested had poor activity against M. tuberculosis isolates (MIC90 8.0 mg/L). Furthermore, high MIC90s of the quinolones and macrolides (20 to 80 mg/L) were obtained for clinical isolates of atypical mycobacteria, with the exception of clarithromycin against M. kansasii (MIC90 = 1.0 mg/L) and sparfloxacin against M. scrofulaceum (MIC90 = 1.0 mg/L). © 1994 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:343 / 351
页数:9
相关论文
共 37 条
[31]  
TSUKAMURA M, 1985, AM REV RESPIR DIS, V131, P352
[32]   SUSCEPTIBILITY OF MYCOBACTERIUM-KANSASII TO OFLOXACIN, SPARFLOXACIN, CLARITHROMYCIN, AZITHROMYCIN, AND FUSIDIC ACID [J].
WITZIG, RS ;
FRANZBLAU, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1997-1999
[33]   INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-AVIUM COMPLEX TO THE NEW FLUOROQUINOLONE SPARFLOXACIN (CI-978-AT-4140) AND COMPARISON WITH CIPROFLOXACIN [J].
YAJKO, DM ;
SANDERS, CA ;
NASSOS, PS ;
HADLEY, WK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2442-2444
[34]   INVITRO ACTIVITY OF OFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS AND ITS CLINICAL EFFICACY IN MULTIPLY RESISTANT PULMONARY TUBERCULOSIS [J].
YEW, WW ;
KWAN, SY ;
MA, WK ;
KHIN, MA ;
CHAU, PY .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (02) :227-236
[35]   AZITHROMYCIN FOR TREATMENT OF MYCOBACTERIUM-AVIUM-INTRACELLULARE COMPLEX INFECTION IN PATIENTS WITH AIDS [J].
YOUNG, LS ;
WIVIOTT, L ;
WU, M ;
KOLONOSKI, P ;
BOLAN, R ;
INDERLIED, CB .
LANCET, 1991, 338 (8775) :1107-1109
[36]   MYCOBACTERIUM-AVIUM COMPLEX INFECTION [J].
YOUNG, LS .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (05) :863-867
[37]  
YOUNG LS, 1987, AM J MED S4A, V82, pS23